Atossa Therapeutics, Inc. (ATOS)
2.445
+0.02
(+1.03%)
USD |
NASDAQ |
Oct 09, 16:00
2.445
0.00 (0.00%)
After-Hours: 16:07
Atossa Therapeutics Max Drawdown (5Y) : 98.59% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 98.59% |
| August 31, 2026 | 98.59% |
| July 31, 2026 | 98.59% |
| June 30, 2026 | 98.59% |
| May 31, 2026 | 96.95% |
| April 30, 2026 | 96.95% |
| March 31, 2026 | 97.83% |
| February 28, 2026 | 97.83% |
| January 31, 2026 | 98.00% |
| December 31, 2025 | 99.22% |
| November 30, 2025 | 99.28% |
| October 31, 2025 | 99.28% |
| September 30, 2025 | 99.28% |
| August 31, 2025 | 99.28% |
| July 31, 2025 | 99.28% |
| June 30, 2025 | 99.28% |
| May 31, 2025 | 99.28% |
| April 30, 2025 | 99.50% |
| March 31, 2025 | 99.67% |
| February 28, 2025 | 99.78% |
| January 31, 2025 | 99.78% |
| December 31, 2024 | 99.78% |
| November 30, 2024 | 99.78% |
| October 31, 2024 | 99.78% |
| September 30, 2024 | 99.78% |
| Date | Value |
|---|---|
| August 31, 2024 | 99.78% |
| July 31, 2024 | 99.78% |
| June 30, 2024 | 99.78% |
| May 31, 2024 | 99.78% |
| April 30, 2024 | 99.78% |
| March 31, 2024 | 99.78% |
| February 29, 2024 | 99.78% |
| January 31, 2024 | 99.78% |
| December 31, 2023 | 99.82% |
| November 30, 2023 | 99.84% |
| October 31, 2023 | 99.84% |
| September 30, 2023 | 99.84% |
| August 31, 2023 | 99.86% |
| July 31, 2023 | 99.86% |
| June 30, 2023 | 99.86% |
| May 31, 2023 | 99.86% |
| April 30, 2023 | 99.86% |
| March 31, 2023 | 99.86% |
| February 28, 2023 | 99.86% |
| January 31, 2023 | 99.86% |
| December 31, 2022 | 99.86% |
| November 30, 2022 | 99.88% |
| October 31, 2022 | 99.88% |
| September 30, 2022 | 99.88% |
| August 31, 2022 | 99.88% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Immix Biopharma, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Savara, Inc. | 93.79% |
| Vericel Corp. | 73.97% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -64.04 |
| Beta (5Y) | 1.274 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 75.18% |
| Historical Sharpe Ratio (5Y) | -0.6822 |
| Historical Sortino (5Y) | -1.241 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 29.12% |